josé manuel pereira - noticias e destaques manuel pereira... · josé manuel pereira ......
TRANSCRIPT
José Manuel Pereira
Serviço de Medicina Intensiva do Hospital S. João
Faculdade de Medicina do Porto
Grupo de Infecção e Sepsis
� Candida species are the most common cause of
invasive fungal infections
Wisplinghoff H et al. Clin Infect Dis 2004;39:309-317
25 hospitals , 9613 blood isolates
Fluit AC et al. Clin Infect Dis 2000; 30: 454-460
Other5%
PICU2%
Other8%
PICU3%
SICU17%
1996-2000
(n=309)
2004-2006
(n=566)
Medical32%
Surgical31%
SICU22%
MICU8%
Medical31%
Surgical26%
17%
MICU15%
Marchetti O et al. Clin Infect Dis 2004;38:311-20 Ongoing prospective study
� Candida species are the most common cause of
invasive fungal infections
� Candidemia is the 4th – 8th most common cause of
nosocomial BSI
� 1/3 of the episodes of candidemia occurs in the ICU
� Risk factors are well known bur rather non-specific
� New diagnostic tools and soring systems may help to
improve the management of patients with IC
� Overall mortality of candidemia is in the range of 25-
40%
Zaoutis TE et al. Clin Infect Dis 2005; 41:1232-9
The impact of Candidemia on excess mortality, increased length of
stay and the burden of cost of hospitalization underscores the need
for improved means of prevention and treatment candidemia
Pappas PG et al. Clin Infect Dis 2009; 48: 503-535
The The English planEnglish plan The Brasilian planThe Brasilian plan
The The French planFrench planThe Portuguese planThe Portuguese plan
Initial therapy
� Fluconazole: 12 mg/Kg (LD) → 6 mg/Kg/d
� Echinocandin:
- Caspofungin: 70 mg (LD) → 50 mg/d
- Anidulafungin: 200 mg (LD) → 100 mg/d- Anidulafungin: 200 mg (LD) → 100 mg/d
- Micafungin: 100 mg/d
Alternatives
� AmB deoxycholate: 0,5-1 mg/Kg/d
� Lipid formulation of AmB: 3-5 mg/Kg/d
A I
Empirical treatment for suspected Invasive Candidiasis
� Fluconazole: 12 mg/Kg (LD) → 6 mg/Kg/d
� Echinocandin:
- Caspofungin: 70 mg (LD) → 50 mg/d
- Anidulafungin: 200 mg (LD) → 100 mg/d- Anidulafungin: 200 mg (LD) → 100 mg/d
- Micafungin: 100 mg/d
Alternatives
� AmB deoxycholate: 0,5-1 mg/Kg/d
� Lipid formulation of AmB: 3-5 mg/Kg/d
BIII
Su
cce
ssfu
l ou
tco
me
s (%
)
40
60
80
100
73,4%
61,7%
80,7%
64,9%
Mora-Duarte J, et al. N Engl J Med. 2002;347:2020-2029.
Su
cce
ssfu
l ou
tco
me
s (%
)
Successful outcome = symptom resolution and microbiological clearance
0
20
4064,9%
Modified ITT(n= 224)
Evaluable patients(n= 185)
CaspoAmB AmBCaspo
p= 0,09 p= 0,03
Favorable overall response at end of i.v. therapy (MITT)Patients (%)
Mora-Duarte et al, N Engl J Med 2002; 347: 2020
Pathogen
C. albicans C. glabrata C. parapsilosis C. tropicalis
� Randomized, double-blind, multicenter, non-inferiority study
� Micafungin (100 mg/d) vs. Liposomal Amphothericin B (3 mg/Kg/d)
� n= 531 pts (ICU patients > 45%)
� Candida albicans: 44%
80
100 89,6
74,1
89,5
69,6
rate
(%
)
Kuse ER et al. Lancet 2007; 369: 1519-1527
0
20
40
60
80
Overall success MITT
Micafungin (n= 202) L-AmB (n= 190)
Su
cce
ssfu
l ra
te (
%)
� Phase III, randomized, double-blind, multicenter, non-inferiority study
� Anidulafungin 200/100 mg/d vs. Fluconazole 800/400 mg/d
� n= 261 pts (25 pts enrolled in one center)
� Candida albicans: 62%
9089,5
0
10
20
30
40
50
60
70
80
90
End IV Tx 2-week FU 6-week FU
75,6
64,6
55,9
49,244,1
Anidulafungin
Fluconazole
Su
cce
ssfu
l ra
te (
%)
p= 0,01 p< 0,02
Reboli AC et al. NEJM 2007; 356: 242-282
� Frequency and type of side effects were similar in both groups:
�24,4% anidulafungin vs. 26,4% fluconazole
� Candidemia only (n= 219 patients)
� Anidulafungin 75,9% vs. Fluconazole 61,2% p= 0,02
� Other forms of Invasive Candidiasis (n= 26 patients)
� Anidulafungin 72,7% vs. Fluconazole 53,3%
Reboli AC et al. NEJM 2007; 356: 242-282
Moderately severe to severe ill Echinocandin A III
Recent azole exposure Echinocandin A IIIRecent azole exposure Echinocandin A III
Less critically ill patient and no recent
azole exposureFluconazole A III
Candida glabrata or Candida krusei Echinocandin B III
Candida parapsilosis Fluconazole B III
GUIDELINESGUIDELINES
Is that what is most needed to
improve outcome ?
New
antifungals
Better and
earlier
TO IMPROVE OUTCOMETO IMPROVE OUTCOME
EARLIER AND BETTER EARLIER AND BETTER
TREATMENTTREATMENT
earlier
diagnosticsBetter
therapeutic
strategy
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
Each hour of delay in antimicrobial administration over the ensuing 6 hours
associated with an average decrease in survival of 7,6%
By multivariate analysis, time to initiation of effective antimicrobial therapy
the single strongest predictor of outcome
Kumar A et al. Crit Care Med 2006; 34: 1589-1596
all
documented
suspected
culture +
culture -
bacteremia +
bacteremia -
community
nosocomial
1385
769
608
1546
459
1695
2154N
912
1242
Adjusted Odds Ratio of Death
1.0 1.1 1.2 1.3
nosocomial
gram +
gram -
fungal
respiratory
urinary tract
intra-abdominal
skin/soft tissue
912
768
584
838
131
230
156
641
Survival =
0.79/1.119x
x = delay (hrs)
Kumar A et al. Crit Care Med 2006; 34: 1589-1596
EtiologyEtiology All casesAll cases 00--2 h delay2 h delay 22--12 h12 h delaydelay > 12 h delay> 12 h delay
Bacteria Number (#) 2866 701 1279 706
% of total # 26,1 47,6 26,3
% survival 47,7 77,3 48,2 16
Candida Number (#) 308 16 62 230
% of total # 5,2 20,1 74,7
% survival 17,5 81,3 41,9 6,5
Median time to initiation of effective antimicrobial therapy in septic shock:
5,5 h for bacteria vs. 35,1 h for Candida
Kumar A et al. 47th ICAAC, Chicago, September 2007 K-2174
Independent determinants of
hospital mortality
� APACHE II score (p <0.001)� APACHE II score (p <0.001)
� Prior antibiotics (p = 0.028)
� Antifungal therapy 12 hours
after the first positive blood
culture (p = 0.018)
94,3% of the patients
hours
Morrell M et al. Antimicrob Agents Chemother 2005; 49: 3640-3645
• Retrospective cohort study of 230 pts
• 70% with non-surgical hospital admission
• C. albicans: 56% pts
• 192 pts with no previous fluconazole tx
� A delay in the initiation of fluconazole therapy in hospitalized patients with
candidemia significantly impacted mortality
� New methods to avoid delays in appropriate antifungal therapy, such as rapid
diagnostic tests or identification of unique risk factors, are needed
Garey KW et al. Clin Infect Dis 2006; 43:25 - 31
• 192 pts with no previous fluconazole tx
� Prior abdominal surgery
� Central venous catheter
� Acute renal failure
� Parenteral nutrition
Multiple antibiotics
� Corticosteroids
� Neutropenia
� Chemotherapy
� Malignancy
Haemodialysis� Multiple antibiotics
� Length of ICU stay > 7 days
� Candida isolated from
other sites
� Haemodialysis
� Burns
� Pancreatitis
� Severity of illness
Fungal colonization index1
� Colonization at multiple sites associated with increased risk of invasive
Candida infection
“Candida Score”2
� Score ≥ 2.5 predictive
Independent Risk Factors Points
Clinical sepsis 2
Surgery on ICU admission 1 Score ≥ 2.5 predictive
of invasive fungal infection
- 81% sensitivity
- 74% specificity
BAMSG predictive rule for identifying high risk patients3
�≥4 ICU days, CVC, diabetes mellitus, new hemodialysis, parenteral nutrition,
broad spectrum antibiotics
- Invasive candidiasis rate: 16.6%
- Captured 78% of patients who developed invasive candidasis
Surgery on ICU admission 1
Total parenteral nutrition 1
Multifocal Candida colonization 1
Note: BAMSG=Bacteriology and Mycology Study Group1Pittet D et al. Ann Surg 1994;220:751-758; 2Leon C et al. Crit Care Med 2006;34:730-737;
3Paphitou NI et al. Med Mycol 2005;43:235-43
One major
Any systemic antibiotic (D1 – D3)
Presence of CVC (D1 – D3)
AND
Sensitivity 34 %
Specificity 90 %AND
At least two minor
Total parenteral nutrition (D1 – D3)
Any dialysis (D1 – D3)
Any major surgery (D -7 – D0)
Pancreatitis (D -7 – D0)
Use of steroids (D -7 – D3)
Use of other immunosupressive agents (D -7 – D0)
Specificity 90 %
PPV 10 %
NPV 97 %
Relative risk 4,36
Ostrosky-Zeichner O et al. Eur J Clin Microbiol Infect Dis 2007; 26: 271-276
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
Pfaller MA et al. J Clin Microbiol 2008; 46:150-156
Breakthrough (n=49)Non-Breakthrough (n=430)
Uzun O et al. Clin Infect Dis 2001;32:1713-17
Mortality: 50% vs. 76%
24% of all episodes of
Candida glabrata fungemia
were associated with receipt
Malani A et al. CID 2005; 41:975-981
were associated with receipt
of an antifungal agent
within 30 days before onset;
In 85% of these the
antifungal was fluconazole
SpeciesSpecies Frequency Frequency %%
FluFlu ItraItra AmBAmB VoriVori PosaPosa CandinsCandins
C. albicansC. albicans 4646 SS SS SS SS SS SS
C. glabrataC. glabrata 2020 SS--DDDD//RR SS--DDDD//RR SS//II SS//II SS//II SS
C. parapsilosisC. parapsilosis 1414 SS SS SS SS SS SS//II
NOTE: Mixed species/others ~5%
S=Susceptible S-DD=Susceptible-Dose Dependent I=Intermediate R=Resistant
C. tropicalisC. tropicalis 1212 SS SS SS SS SS SS
C. kruseiC. krusei 22 RR SS--DDDD//RR SS SS SS SS
C. dubliniensisC. dubliniensis <1<1 SS//SS--DDDD SS SS//II SS//II SS//II SS
C. lusitaniaeC. lusitaniae <1<1 SS SS SS//RR SS SS SS
Pappas PG et al, Pappas PG et al, ClinClin Infect Infect DisDis 2004;38:1612004;38:161--89; 89; BartizalBartizal K et al, K et al, AntimicrobAntimicrob Agents Agents ChemotherChemother 1997;41:23261997;41:2326--32; 32; Patterson TF. Patterson TF. J J ChemotherChemother 1999;11:5041999;11:504--12; 12; PfallerPfaller MA et al, MA et al, AntimicrobAntimicrob Agents Agents ChemotherChemother 2002;46:17232002;46:1723--7; 7;
PfallerPfaller MA et al, MA et al, J J ClinClin MicrobiolMicrobiol 2002;40:8522002;40:852--66
SpeciesSpecies Frequency Frequency %%
FluFlu ItraItra AmBAmB VoriVori PosaPosa CandinsCandins
C. albicansC. albicans 4646 SS SS SS SS SS SS
C. glabrataC. glabrata 2020 SS--DDDD//RR SS--DDDD//RR SS//II SS//II SS//II SS
C. parapsilosisC. parapsilosis 1414 SS SS SS SS SS SS//II
NOTE: Mixed species/others ~5%
S=Susceptible S-DD=Susceptible-Dose Dependent I=Intermediate R=Resistant
C. tropicalisC. tropicalis 1212 SS SS SS SS SS SS
C. kruseiC. krusei 22 RR SS--DDDD//RR SS SS SS SS
C. dubliniensisC. dubliniensis <1<1 SS//SS--DDDD SS SS//II SS//II SS//II SS
C. lusitaniaeC. lusitaniae <1<1 SS SS SS//RR SS SS SS
Pappas PG et al, Pappas PG et al, ClinClin Infect Infect DisDis 2004;38:1612004;38:161--89; 89; BartizalBartizal K et al, K et al, AntimicrobAntimicrob Agents Agents ChemotherChemother 1997;41:23261997;41:2326--32; 32; Patterson TF. Patterson TF. J J ChemotherChemother 1999;11:5041999;11:504--12; 12; PfallerPfaller MA et al, MA et al, AntimicrobAntimicrob Agents Agents ChemotherChemother 2002;46:17232002;46:1723--7; 7;
PfallerPfaller MA et al, MA et al, J J ClinClin MicrobiolMicrobiol 2002;40:8522002;40:852--66
Candida Candida
albicans non-albicans Azole-
Susceptible
Azole-
Resistant
“For infections due to to Candida parapsilosis,
Fluconazole is preferred as initial therapy (BIII)”
Pappas PG et al. Clin Infect Dis 2009; 48: 503-535
Shorr et al. Crit Care Med 2007; 35: 1077-1083
� No variable, including both previous fluconazole and severity of illness, correlated
Chow JK et al. Clin Infect Dis 2008; 46: 1206-1213
� Receipt of fluconazole� Receipt of fluconazole
� Central venous exposure
Lin et al. Antimicrob Ag Chemother 2005; 49: 4555-4560
� Certain antibacterial were associated with Candida glabrata/ krusei BSI
Playford EG et al. Crit Care Med 2008; 36:2034-2039
� Prior antifungal exposure
� Gastrointestinal surgical procedures
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
Stage 1
� Administering broad-spectrum antibiotics therapy to improve
outcomes (decrease mortality, prevent organ dysfunction and
decrease length of stay)
Stage 2
� Focusing on de-escalating as a means to minimize resistance
and to improve cost-effectiveness*
Transition or stepdowtherapy in the IDSA guidelines for
invasive candidiasis
* In some cases to cover resistant pathogens not covered with the initiaal regimen, to
provide source control or to treat fungal pathogens
Echinocandin → FluconazoleClinically stable + isolate
susceptible to fluconazoleA II
Clinically stable + isolate AmB-D, L-AmB → Fluconazole
Clinically stable + isolate
susceptible to fluconazoleA I
Step-down therapyVoriconazole
(VRC-S C. glabrata or krusei)B III
Sensitivity > 55%;
False + in bacteremia
Specificity 96%; High NPV
If negative, stop
Senn L et al. CID 2008; 46: 878-885
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
BOTTOM LINE
HIGHER DOSING
=
BETTER OUTCOME
Manjunath PP et al. Antimicrob Agents Chemother 2007; 51(1): 35-39
� Dose dependent antifungal activity in rabbit aspergillosis
Petraitene R et al. Antimicrob Agents Chemother 2001; 45: 857-69
� Higher plasma concentrations associated with higher
response rates in humansresponse rates in humans
Walsh TJ et al. CID 2007; 44: 2-12
Keeping voriconazole trough levels inside the therapeutic range of 1-
5,5 mg/l during the first week of therapy may prevent treatment
failures and neurological toxicity.
Pascual A et al. CID 2008; 46: 201-211
AMB deoxAMB deox LL--AMBAMB FLUCOFLUCO VORICOVORICO ECHINOECHINO
CNS penetration
%< 10 < 10 80 90 NA
%< 10 < 10 80 90 NA
SNC:
- Linear relationship between the voriconazole dose and CSF concentration
- Median CSF : plasma concentration ratio of 0,5
Pearson MM et al. Ann Pharmacother 2003; 37: 420-32
� Candidemia causes chorioretinitis in 10% of patients
� Candins diffuse poorly into the eye and are notindicated, at least as the sole antifungal to treatendophthalmitis.
� However, published studies have not reported greater� However, published studies have not reported greaterlevels of failure in patients with chorioretinitis treatedwith a candin
� Although urinary elimination of candins is < 3%, limitedexperience with caspo for candiduria has beenfavorable
Khan FA et al. Pharmacotherapy 2007; 27: 1711-21
Sobel JD et al. Clin Infect Dis 2007; 44: 46-49
1st choice Alternative Duration
Cystitis Fluconazole (3 mg/Kg) If F-R AmB-d 0,3-0,6 mg/Kg/dF – 2 w
AmB d – 7 d
Pyelonephritis Fluconazole (3-6 mg/Kg) If F-R AmB-d 0,5-0,7 mg/Kg/d 2 w
Osteomyelitis *Fluconazole (3-6 mg/Kg)
LFAmB 3-5 mg/Kg/d6-12 monthsOsteomyelitis *
LFAmB 3-5 mg/Kg/d6-12 months
CNS* LFAmB 3-5 mg/Kg/d Several weeks
EndophtalmitisAmB-d 0,7-1 mg/Kg/d
Fluconazole**
LFAmB
Echinocandins
Voriconazole
4-6 w
Endocarditis* LFAmB 3-5 mg/Kg/d *AmB-d 0,6-1 mg/Kg/d
Echinocandins (higher doses)
6 w after valve
replacement
* Fluconazole (6-12 mg/Kg/d) as stepdown therapy
** For less severe cases
AMB deox L-AMB FLUCO VORICO CASPOANIDULA
and MICA
Renal failureRenal failure NoNo NoNo YesYes No *No * NoNo NoNo
Moderate liverModerate liver
failurefailureNoNo NoNo NoNo YesYes YesYes NoNo
* IV vorico* IV vorico contraindicated if Cr Cl < 50 ml/mincontraindicated if Cr Cl < 50 ml/min
France 1 USA 2
Risk of PPDI 27% 70%
Rifampicin (45%)
Cyclosporin (40%)
Prednisone (25%)
Midazolam (18%)
Potential interactions
Cyclosporin (40%)
Glimepiride (10%)
Glibenclamide (5%)
Midazolam (18%)
Warfarin (15%)
Methylprednisolone (14%)
Cyclosporine (11%)
Nifedipine (10%)
1 Depont F et al. Pharmacoepidemiol Drug Saf 2007; 16: 1227-1233
2 Yu DT et al. Pharmacoepidemiol Drug Saf 2005; 14: 755-767
Caspofungin- Efavirenz, carbamazepine, phenytoin, phenobarbital or dexhametasonecan reduce efficacy of caspo and doses should be increased to 70 mg/day
- Rifampicin usually reduces levels of caspo by approximately 30%, thus a 70mg daily (q.d.) dose may be recommended for persons receiving both rifampin and caspofungin (?)
- Caspo decreases serum levels of tacrolimus by 20%
- Cyclosporin increases caspo plasma concentrations by 35% but no significant adverse events have been reported, so prior recommendations to avoid the use of adverse events have been reported, so prior recommendations to avoid the use of cyclosporine and caspofungin concomitantly are largely not applicable anymore.
MicafunginMay increase the blood levels of drugs metabolized by the cytochrome P450 (CYP)3A4 system
Is a mild inhibitor of cyclosporine metabolism, cyclosporine levels should be monitored
Serum concentrations of sirolimus and nifedipine increase by 21 and 18%, respectively and their levels should be monitored
Stone JA et al. Antimicrob Agents Chemother 2004; 48: 4306-14
Hebert MF et al. J Clin Pharmacol 2005; 45: 954-60
Trissel L et al. Am J Health Syst Pharm 2005; 62: 834-7
The echinocandins caspofungin and micafungin The echinocandins caspofungin and micafungin
undergo hepatic degradation undergo hepatic degradation
via hydrolysis and Nvia hydrolysis and N--acetylation, acetylation,
Metabolism:Metabolism:
> 90% chemical degradation in the blood> 90% chemical degradation in the blood
Bypasses hepatic metabolismBypasses hepatic metabolism
Control
Fluconazole
Itraconazole
KetoconazoleFlucytosine
Fungicidal activity against Fungicidal activity against C.C. albicansalbicans
1.0E+06
1.0E+07
1.0E+08
Log
CF
U/m
L
Zhanel G et al. Antimicrob Agents Chemother. 2001;45:2018-2022.
Flucytosine
Ampho B
Concentrations used were the MIC of each compound
0 5 10 15 20 25
1.0E+02
1.0E+03
1.0E+04
1.0E+05
Time (hours)
Log
CF
U/m
L
Anidulafungin
� Candida spp. adhere to inert and biological surfaces – associated with virulence
� Catheter-related infections
� Biomaterial surfaces (implants, dentures, prostheses)
Candida albicans biofilm
dentures, prostheses)
� Biofilm-associated infections (endocarditis, oropharyngealcandidiasis)
� High level of antifungal resistance
� Fluconazole & polyene resistance
� Echinocandin susceptibility
Bachmann SP, et al. Antimicrob Agents Chemother 2002;46:3591-6; Ramage G, et al. Antimicrob Agents Chemother 2002;46:3634-6
Non-neutropenic patients
� Catheter frequently implicated—change indicated
� Unless other obvious source (urine, abscess)
Neutropenic patients
� Mucositis: gut source
� Tunneled line removal may be difficult & benefit less clear
Candida parapsilosis
� Strongly catheter-associated
� Very difficult to eradicate without line removal
Rex JH et al. CID 1995; 21: 994-996
Echinocandin → FluconazoleClinically stable + isolate
susceptible to fluconazoleA II
AmB-D, L-AmB → FluconazoleClinically stable + isolate
susceptible to fluconazoleA I
Step-down therapyVoriconazole
(VRC-S C. glabrata or krusei)B III
Duration of therapy
2 w after clearance of
Candida BSI and resolution of
symptoms
A III
IV catheter removal All A II
� Earlier therapy Clinical suspicion
� Mycological diagnosis Directed therapy
� De-escalation / Transition
� Use PK/PD knowledge
� Indication for combination
� Randomized, blinded, multicenter trial
� Fluconazole (800mg/d) + Placebo vs. Fluconazole (800 mg/d) + Ampho B
(0,6-0,7 mg/Kg) for 5-7 days
� n= 219 patients with candidemia (except C. krusei)
Successful outcome
Monotherapy 56%
vs.
Combination therapy 69%
p= 0,043
Rex JH et al. CID 2003; 36: 1221-1228
Combination Monotherapy p=
Time to failure 69% 57% 0,08
Persistent candidemia 6 % 17% 0,02
Duration of therapy 15 16,7 0,123
Nephrotoxicity 23% 3% < 0,001
Mortality within 90 days 40% 39% NS
CONCLUSION
In non neutropenic patients, the combination of fluconazole plus AmBwas not antagonistic compared with fluconazole alone, and thecombination trended toward improved sucess and more rapid clearancefrom the bloodstream
Rex JH et al. CID 2003; 36: 1221-1228
Pachl et al. CID 2006; 42: 1404-1413
Mycograb plus lipid–associated amphotericin B produced
significant clinical and culture confirmed improvement in
outcome for patients with invasive candidiasis
Host Host & fungus adapted antifungal & fungus adapted antifungal therapytherapy
Patient-based decisions
Host Host & fungus adapted antifungal & fungus adapted antifungal therapytherapy
� High level of clinical suspicion
� Early antifungal therapy
� Remove CVC
� Mycological diagnosis
� PK / PD
� Direct / Stepdown / Transition
� Monitor response: fundoscopic exam &
negative blood cultures
20
30
40
5049
4740
38
45
42
48
38
39
35
0
10
20
4
17
8 69
dist
ribut
ionn
(%
)
20
30
40Bacterial septic shock (n=3590); median 5.5 hrCandida septic shock (n=443); median 35.1 hr
time to effective antimicrobial (hrs)0-2 hrs2-6 hrs6-12 hrs12-24 hrs24-72 hrs72+ hrs
dist
ribut
ionn
(%
)
0
10
20
Sur
viva
l (%
)
60
80
100Bacterial septic shock (n=3590)Candida septic shock (n=443)
Time to effective antimicrobial (hrs)0-2 hrs2-6 hrs6-12 hrs12-24 hrs24-72 hrs72+ hrsAll
Sur
viva
l (%
)
0
20
40
Sur
viva
l (%
to
tal)
50
60
70
80
fungal (n=131)
bacterial (n=1925)
69
Antimicrobial Initiation Delay
Sur
viva
l (%
0
10
20
30
40
Overall 0-2hr 2-6 hr 6-12 hr >12 hr
2004 2009
Neutropenia Severity of illness
Azole exposure
C. glabrata and krusei local
prevalence
Antifungal spectra differ between the three major antifungal classes, and even between agents within the classes, and impact on the choice of antifungal drug
Invasive candidiasis if severe or in centres with fluco Invasive candidiasis if severe or in centres with fluco resistance > 24% :resistance > 24% : Caspo or AnidulafunginCaspo or Anidulafungin
Candida glabrataCandida glabrata or or kruseikrusei:: Caspo or AnidulafunginCaspo or Anidulafungin
Candida parapsilosisCandida parapsilosis:: FluconazolFluconazol
� High level of clinical suspicion
� Early antifungal therapy
� Remove CVC
CONCLUSIONS:CONCLUSIONS:BETTER BETTER STRATEGYSTRATEGY
� Remove CVC
� PK / PD
� Mycological diagnosis
� Direct / Stepdown / Transition
� Monitor response: fundoscopic exam &
negative blood cultures
�� Invasive candidiasis if severe or in centres with fluco resistance > Invasive candidiasis if severe or in centres with fluco resistance > 24% :24% : EchinocandinEchinocandin
�� Candida Candida glabrataglabrata or or kruseikrusei:: EchinocandinEchinocandinCandida Candida glabrataglabrata or or kruseikrusei:: EchinocandinEchinocandin
�� Candida Candida parapsilosisparapsilosis:: FluconazoleFluconazole
PK/PD attributes and toxicity profiles of the antifungal agents are of paramount importance, as they allow antifungal choice to adapt to the host characteristics
� Concomitant use of CYP metabolised drugs: Anidulafungin
� Renal failure: No IV voriconazole and no Ampho B
� Meningitis or endophtalmitis or urinary: Voriconazole or fluconazole
� Biofilm (CVC, biomaterial, endocarditis): Echinocandin
squalenessqualenes
allylaminesallylamineseg terbinafineeg terbinafineallylaminesallylamineseg terbinafineeg terbinafine
acetylacetyl--CoCo--AAnucleosidesnucleosideseg 5eg 5--flucytosineflucytosinenucleosidesnucleosideseg 5eg 5--flucytosineflucytosine
nucleic acid synthesisnucleic acid synthesis
echinoocandinsechinoocandinseg caspofungineg caspofunginechinoocandinsechinoocandinseg caspofungineg caspofungin
glucan synthesisglucan synthesis
ergosterolergosterol
polyenespolyeneseg amphotericin Beg amphotericin Bpolyenespolyeneseg amphotericin Beg amphotericin B
azolesazoleseg fluconazoleeg fluconazoleazolesazoleseg fluconazoleeg fluconazole
squalenessqualenes
lanosterollanosterolKK++
Mg Mg 2+2+
eg caspofungineg caspofungineg caspofungineg caspofungin
nikkomycinsnikkomycinsnikkomycinsnikkomycinschitin synthesischitin synthesis
azasordarinsazasordarinsazasordarinsazasordarinsprotein synthesisprotein synthesis
40
50
60
70
Mo
rta
lity
(%
)
Crude & Attributable Mortality in
Nosocomial Candidemia
57%
38%
49%
61%
0
10
20
30
40
1983-1986 1997-2001
Mo
rta
lity
(%
)
Crude mortality
Attributable
mortality
Wey et al Arch Intern Med 1988;148:2642-5; Gudlaugsson et al Clin Infect Dis 2003;37:1172-7
Wisplinghoff H et al. CID 2004; 39:309-317
Benefits
� Reduce toxicity
� Increase tissue penetration
� Reduce risk of resistance� Reduce risk of resistance
� Improve efficacy (fungistatic drugs)
Disadvantages
� Risk of antagonism
� Price